• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

    4/30/24 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECH alert in real time by email

    MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent.

    Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various senior global clinical and research positions at Novartis Oncology, a division of Novartis AG, including SVP & Global Head, Oncology Clinical Development. Dr. Klimovsky also served as Regional Medical Director, Latin America for Merck & Co. and held several research and development roles of increasing responsibility at Bristol-Myers Squibb Company. Dr. Klimovsky received her M.D. from the Universidad de Buenos Aires.

    Dr. Klimovsky previously (from 2018 to Feb 2024) served as a Director of Bellicum Pharmaceuticals, a company discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors.  

    "We are pleased to welcome Dr. Klimovsky to our board," said Bob Baumgartner, Chairman of the Board of Bio-Techne. "She brings tremendous scientific and international experience, including running large development groups at global biopharma companies. She also has extensive experience in Latin America, which will bring important expertise as Bio-Techne continues to expand globally."

    About Bio-Techne Corporation (NASDAQ:TECH) 

    Contact:

    David Clair, Vice President, Investor Relations & Corporate Development

    [email protected] 

    612-656-4416

    Bio-Techne Logo (PRNewsfoto/Bio-Techne Corporation)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-appoints-dr-judith-klimovsky-to-board-of-directors-302129811.html

    SOURCE Bio-Techne Corporation

    Get the next $TECH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TECH

    DatePrice TargetRatingAnalyst
    5/30/2025$59.00Overweight
    Wells Fargo
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/18/2025$75.00Outperform
    Evercore ISI
    2/19/2025$88.00 → $68.00Outperform → Neutral
    Robert W. Baird
    5/22/2024$85.00Buy → Neutral
    Citigroup
    2/8/2024$80.00Sector Outperform
    Scotiabank
    2/2/2024$65.00Buy → Hold
    Stifel
    12/7/2023$80.00Buy
    UBS
    More analyst ratings

    $TECH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

      ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. "The blood cancer burden on India's population is substantial, around 120,000 new cases of lymphoma, leukemia, and multiple myeloma are diagnosed each year. Unfortunately, almost 70,000 Indians will die every year from these afflictions, devastating the lives of their families and communities. To afford access to all Indian patients in need,

      6/10/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne to Present at Investor Conferences

      MINNEAPOLIS, May 29, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that it will present at the following investor conferences: William Blair 45th Annual Growth Stock ConferenceJune 3, 20252:40 PM CDT Jefferies Global Healthcare ConferenceJune 4, 20253:45 PM EDT Goldman Sachs 46th Annual Global Healthcare ConferenceJune 10, 202510:40 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-TechneBio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and cli

      5/29/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA)

      ST. PAUL, Minn., May 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ:TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA). The funding totaling $1,025,000 will support the translation of various cell and gene therapy initiatives into the clinic. Dr. Mohamed Abou-el-Enein, Executive Director of the USC/CHLA Cell Therapy Program and Founding Director of the cGMP Facility, received a $300,000 G-Rex Grant to further support the development of a novel non-viral manufacturing platform for CA

      5/14/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Bio-Techne with a new price target

      Wells Fargo initiated coverage of Bio-Techne with a rating of Overweight and set a new price target of $59.00

      5/30/25 8:40:12 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Bio-Techne from Overweight to Sector Weight

      4/9/25 8:34:38 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Bio-Techne with a new price target

      Evercore ISI initiated coverage of Bio-Techne with a rating of Outperform and set a new price target of $75.00

      3/18/25 7:57:08 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    SEC Filings

    See more
    • SEC Form 144 filed by Bio-Techne Corp

      144 - BIO-TECHNE Corp (0000842023) (Subject)

      6/9/25 4:19:36 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SD filed by Bio-Techne Corp

      SD - BIO-TECHNE Corp (0000842023) (Filer)

      5/30/25 4:30:27 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Bio-Techne Corp

      SCHEDULE 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      5/14/25 10:45:26 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Herr Amy E. exercised 1,280 shares at a strike of $44.33 and sold $63,705 worth of shares (1,280 units at $49.77) (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      6/11/25 4:20:06 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Higgins John L exercised 12,000 shares at a strike of $21.84, increasing direct ownership by 25% to 60,196 units (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      5/5/25 4:18:21 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP - General Counsel Bohnen Shane converted options into 2,260 shares and covered exercise/tax liability with 747 shares, increasing direct ownership by 90% to 3,194 units (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      4/7/25 4:25:38 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Leadership Updates

    Live Leadership Updates

    See more
    • Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

      MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th

      2/4/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

      MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s

      4/30/24 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

      MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D

      1/5/24 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care